Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)PRNewsWire • 11/03/20
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology ProductPRNewsWire • 10/30/20
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trialPRNewsWire • 10/22/20
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in BrazilPRNewsWire • 10/15/20
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosisPRNewsWire • 10/13/20
Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeuticsPRNewsWire • 10/01/20
Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDAPRNewsWire • 09/30/20
Why Is Ionis Pharmaceuticals (IONS) Down 2.2% Since Last Earnings Report?Zacks Investment Research • 09/04/20
New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedemaPRNewsWire • 09/02/20
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Akcea Therapeutics, Inc. to Ionis Pharmaceuticals, Inc.Newsfile Corp • 08/31/20
Akcea Therapeutics Rallies After Majority Owner Ionis Agrees To Buy Remaining StakeBenzinga • 08/31/20
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020PRNewsWire • 08/29/20
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020PRNewsWire • 08/29/20
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020PRNewsWire • 08/24/20
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020PRNewsWire • 08/18/20